Trials / Conditions / Stage IVA Squamous Cell Carcinoma of the Oropharynx

Stage IVA Squamous Cell Carcinoma of the Oropharynx

27 registered clinical trials studyying Stage IVA Squamous Cell Carcinoma of the Oropharynx.

Status	Trial	Sponsor	Phase
Terminated	Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer NCT02177838	Rutgers, The State University of New Jersey	N/A
Completed	Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or NCT02258659	University of Chicago	Phase 2
Completed	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	—
Completed	Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511	Mayo Clinic	Phase 2
Active Not Recruiting	Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Trea NCT01898494	ECOG-ACRIN Cancer Research Group	Phase 2
Withdrawn	Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480	Roswell Park Cancer Institute	Phase 1
Completed	Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Sta NCT02048020	Jonsson Comprehensive Cancer Center	Phase 2
Withdrawn	Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal C NCT01953952	Radiation Therapy Oncology Group	Phase 2
Terminated	Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer NCT01949740	University of Chicago	—
Completed	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984	University of Chicago	Phase 1 / Phase 2
Withdrawn	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374	Roswell Park Cancer Institute	Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177	University of Washington	Phase 1
Completed	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627	National Cancer Institute (NCI)	Phase 2
Completed	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435	National Cancer Institute (NCI)	Phase 2
Completed	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767	National Cancer Institute (NCI)	Phase 2
Completed	Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral NCT01504932	Ohio State University Comprehensive Cancer Center	N/A
Completed	Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell NCT00103259	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283	National Cancer Institute (NCI)	Phase 2
Completed	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283	National Cancer Institute (NCI)	Phase 1
Withdrawn	Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity NCT02119728	Roswell Park Cancer Institute	Phase 2